[Advances in the treatment of advanced colorectal cancer]

Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials.

Clinical colorectal cancer·2023

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.

ESMO open·2021

Treatment patterns for metastatic colorectal cancer in Spain.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2020

The burden of cancer in Spain.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2018

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.

European journal of cancer (Oxford, England : 1990)·2018

Hyperprogression as a distinct outcome after immunotherapy.

Cancer treatment reviews·2018

Trends in the structure, activity, and outcomes of Internal Medicine Services in the National Health System (2007-2024): The RECALMIN Study VI.

Revista clinica espanola·2026

Prognostic value of the Edmonton Obesity Staging System among people hospitalized with obesity.

Revista clinica espanola·2026

Utility of an extended 12-autoantibody panel in systemic sclerosis: clinical and prognostic implications in a real-life cohort.

Revista clinica espanola·2026

Joint position paper on anterior ischemic optic neuropathy (AION). Vascular Risk Group and Systemic Autoimmune Diseases Group (GEAS) of the Spanish Society of Internal Medicine (SEMI) together with the Spanish Retina and Vitreous Society (SERV).

Revista clinica espanola·2026

Joint pain: a practical guide to the diagnosis of arthritis.

Revista clinica espanola·2026

Stickler syndrome type 1: case series and new genetic variants.

Revista clinica espanola·2026

Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.

Cancer discovery·2026

Clinical and scintigraphic improvement of mandibular involvement associated with chronic nonbacterial osteitis following an interleukin-23 inhibitor: a case-based literature review.

Immunological medicine·2026

Navigating clozapine discontinuation in clinical practice: An updated framework.

Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists·2026

Early progression after immune checkpoint inhibitor therapy in recurrent or metastatic head and neck squamous cell carcinoma: association with disease distribution in a single-center retrospective study.

Japanese journal of clinical oncology·2026

Evaluation of the protective effects of green tea for ischemia-reperfusion injury in rat ovary tissue: an experimental study.

Acta cirurgica brasileira·2026

Early intervention with clozapine: Is there a neurobiological critical period for treatment-resistant schizophrenia?

Journal of psychopharmacology (Oxford, England)·2026

Related Experiment Videos

[Advances in the treatment of advanced colorectal cancer]

Related Concept Videos

Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials.

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.

Treatment patterns for metastatic colorectal cancer in Spain.

The burden of cancer in Spain.

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.

Hyperprogression as a distinct outcome after immunotherapy.

Trends in the structure, activity, and outcomes of Internal Medicine Services in the National Health System (2007-2024): The RECALMIN Study VI.

Prognostic value of the Edmonton Obesity Staging System among people hospitalized with obesity.

Utility of an extended 12-autoantibody panel in systemic sclerosis: clinical and prognostic implications in a real-life cohort.

Joint position paper on anterior ischemic optic neuropathy (AION). Vascular Risk Group and Systemic Autoimmune Diseases Group (GEAS) of the Spanish Society of Internal Medicine (SEMI) together with the Spanish Retina and Vitreous Society (SERV).

Joint pain: a practical guide to the diagnosis of arthritis.

Stickler syndrome type 1: case series and new genetic variants.

Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.

Clinical and scintigraphic improvement of mandibular involvement associated with chronic nonbacterial osteitis following an interleukin-23 inhibitor: a case-based literature review.

Navigating clozapine discontinuation in clinical practice: An updated framework.

Early progression after immune checkpoint inhibitor therapy in recurrent or metastatic head and neck squamous cell carcinoma: association with disease distribution in a single-center retrospective study.

Evaluation of the protective effects of green tea for ischemia-reperfusion injury in rat ovary tissue: an experimental study.

Early intervention with clozapine: Is there a neurobiological critical period for treatment-resistant schizophrenia?

Related Experiment Videos

[Advances in the treatment of advanced colorectal cancer]

Related Concept Videos

Related Articles